Background: Three-dimensional contrast-enhanced ultrasound (3D-CEUS) is a novel technology allowing surgeons to view duplex ultrasound images in three dimensions with ultrasound contrast highlighting blood flow in endoleaks after endovascular aneurysm repair (EVAR). It potentially reduces the need for computed tomography angiography (CTA) and catheter angiography. This study compares 3D-CEUS with both CTA and the final vascular multidisciplinary team (MDT) diagnosis using all available imaging. Interoperator variability for detection of endoleak and the influence of 3D-CEUS on patient management were studied.
1
Endoleaks may pressurize the abdominal aortic aneurysm (AAA), leading to continued growth and rupture. 1, 2 Surveillance aims to detect device-related complications early, allowing intervention before a complication such as AAA rupture occurs. Computed tomography angiography (CTA) is considered the noninvasive "gold standard" for detection of EVAR-related complications and is used in surveillance programs worldwide. 1, 3 However, CTA may be insensitive to some endoleaks, is expensive, involves ionizing radiation, and causes cumulative renal damage by the nephrotoxic iodinated contrast media. 4 A move from CTA toward ultrasound modalities for EVAR surveillance has been evolving for more than a decade. The optimal program for EVAR surveillance remains uncertain, 5 with early reports suggesting that standard duplex ultrasound is not sensitive enough to replace CTA for endoleak detection. [6] [7] [8] [9] More recently, acceptable detection rates for clinically important endoleaks have been achieved. 10, 11 Contrast-enhanced ultrasound (CEUS) involves the intravenous administration of a stable suspension of sulfur hexafluoride microbubbles surrounded by a phospholipid shell as an lowe@doctors.org.uk).
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Copyright Although the skill of a good vascular laboratory scientist is to interpret standard two-dimensional (2D) duplex images, vascular surgeons are more familiar with CTA, and relying on simple static 2D ultrasound images or short cine loops saved for later viewing means that some may be reluctant to accept these reports, preferring to see the anatomy for themselves. Threedimensional (3D)-CEUS uses magnetic position tracking to enable a computer to assemble all the ultrasound reflections into a 3D image that can be interpreted by any clinician. It allows multiplanar reconstruction and image manipulation in any plane as when using a computed tomography workstation. In a pilot study on 30 paired CTA and 3D-CEUS acquisitions, we reported that 3D-CEUS appeared more accurate than CTA for the detection and classification of endoleaks. 17 We have also reported intraoperative use for completion imaging after EVAR. 18 We now report the final results of a study comparing standard CEUS, 3D-CEUS, and CTA for the detection and classification of endoleaks in EVAR surveillance. Interoperator variability for the detection and classification of endoleak by 3D-CEUS was also studied. Although 3D-CEUS was compared with CTA, the primary end point was to compare standard CEUS, 3D-CEUS, and CTA with the final decision of the vascular multidisciplinary team (MDT) attended by both vascular surgeons and interventional radiologists after review of all the available evidence including catheter angiography when this was needed.
METHODS
Between May 2012 and March 2015, consecutive patients undergoing CTA for EVAR surveillance were invited to take part and underwent 3D-CEUS on the same day when possible. When this was not feasible, they attended as close to the same date as possible, provided this was within the same month. CTA was reported by the consultant vascular interventional radiologists. Standard CEUS and 3D-CEUS images were acquired by the same experienced vascular scientist for all patients in this study and reported independently by two vascular scientists blinded to each other and the CTA result. The learning curve of around 20 cases for vascular scientists reporting in this study was established before commencement. Previous studies have compared ultrasound modalities with CTA as the gold standard, [13] [14] [15] but no single imaging modality has been shown to be completely accurate. We therefore compared 3D-CEUS reports with the final diagnostic decision made in the vascular MDT meeting of vascular surgeons and interventional radiologists with access to all the available evidence, including results from catheter angiography when available. All patients gave informed consent. The study was approved by the National Research Ethics Service (13/NW/0485).
Standard CEUS. CEUS was performed using the same Philips iU22 duplex ultrasound machine (Philips, Amsterdam, The Netherlands) and C5-1 curved array transducer for all patients. A 1-mL bolus of sulfur hexafluoride contrast agent (SonoVue; Bracco, Milan, Italy) was given into a suitable upper limb vein and flushed with 5 mL of 0.9% saline per our departmental protocol. Further 1-to 2-mL boluses were given as required to a maximum of 5 mL, depending on the complexity of the endoleak and how quickly the contrast agent was eliminated by each patient. The "contrast" mode, using a low mechanical index, was selected on the duplex ultrasound instrument to prevent microbubble rupture. The stent graft and AAA were interrogated systematically from neck to limbs. The "flash" function that dissipates contrast material was used to assess the timing, direction of flow, and inflow vessel of any endoleak detected.
3D-CEUS. The 3D ultrasound system used was a prototype magnetically tracked freehand system attached to the same Philips iU22 ultrasound unit. It incorporated a In 100 patients, threedimensional contrast-enhanced ultrasound was more sensitive and accurate than computed tomography angiography for endoleak detection and classification after endovascular aneurysm repair.
ARTICLE HIGHLIGHTS
The authors recommend threedimensional contrast-enhanced ultrasound for patients after endovascular aneurysm repair in cases of sac expansion during duplex ultrasound followup or if there is diagnostic uncertainty on standard duplex ultrasound or computed tomography angiography.
3D guidance system (driveBAY; Ascension Technology Corp, Shelburne, Vt) that uses an electromagnetic field generator with tracking sensors attached to the ultrasound probe. It can be fitted to most commercial ultrasound systems. The information generated by moving the sensor in the magnetic field allowed the source of all ultrasound reflections to be interpreted by the computer. Multiplanar reconstructions and a volumetric image were then computed from the ultrasound frames using these positional data.
To acquire the 3D image, the transducer was placed proximally and swept down the aortic aneurysm in an axial orientation from neck to bifurcation. Another bolus of contrast material was given if needed. Multiplanar reconstructions of these ultrasound data were generated in <5 seconds. A volumetric image that can be manipulated to improve visualization of endoleaks was produced simultaneously and could be manipulated on a touch screen. There were further postprocessing options to improve visualization, but these were rarely needed (Fig 1) .
CTA. CTA was performed using a Siemens SOMATOM Perspective scanner (Siemens Medical, Munich, Germany). Patients were positioned supine, and images at 1-mm slices were acquired from the diaphragm to the femoral heads. A dual-phase protocol was used (arterial and delayed) with a bolus dose of 100 mL of the iodinated contrast medium Omnipaque 240 (GE Healthcare, Buckinghamshire, UK) administered at a flow rate of 3 mL/s. Multiplanar reconstructions were produced and reported by consultant vascular radiologists.
Statistical analysis. Based on pilot study data, a power calculation suggested that a minimum of 67 paired CTA and 3D-CEUS studies were required. Sensitivity, specificity, positive predictive value, and negative predictive value for endoleak detection were calculated using contingency tables and compared with both CTA and the final MDT decision. CTA was the reference as it is commonly used to plan endoleak management and has been the gold standard in all previous studies. The MDT decision was based on all the available evidence including CTA and catheter angiography when this was indicated. The k statistic was used to determine consistency between two observers to detect and to classify endoleaks on 3D-CEUS. Interoperator agreement for endoleak detection and classification using 3D-CEUS was assessed to include subtypes of endoleak; for example, agreement was considered negative if the first operator diagnosed a type IIa endoleak and the second a type IIb endoleak. Analyses were performed using SPSS Statistics v20 (IBM Corp, Armonk, NY).
RESULTS
From some 600 patients in our EVAR surveillance program, 156 consecutive patients due for CTA were invited.
From 99 consenting patients, 102 matched CTA, CEUS, and 3D-CEUS images were acquired. Image quality in two CEUS and 3D-CEUS studies was too poor for diagnosis because of bowel gas or obesity; 100 paired studies were analyzed. There were 86 men and 13 women; mean age was 76 years, and mean body mass index was 28. There were no side effects from the use of microbubbles or radiocontrast agents. CTA and ultrasound imaging was on the same day in 52 studies and never more than 4 weeks apart.
Endoleaks were detected on CTA in 46 patients compared with 49 patients for both CEUS and 3D-CEUS. The final MDT decision determined that there were a total of 51 endoleaks. The frequency of endoleak was higher than in our EVAR surveillance program as patients with potential complications are more likely to be imaged by CTA. The number and type of each endoleak detected by each modality are summarized in the Table, and each is compared with the final diagnostic conclusion reached by the MDT. 3D-CEUS diagnosis compared most closely with the MDT decision.
The total number of endoleaks detected by standard CEUS and 3D-CEUS was the same. Therefore, compared with CTA, the sensitivity, specificity, positive predictive value, and negative predictive value for endoleak detection were 96%, 91%, 90%, and 96%, respectively. Sensitivity was reduced by the failure to detect two endoleaks seen on CTA, one of which was a type Ia endoleak (small and seen in the proximal aneurysm neck) and the other a type II leak with no associated increase in aneurysm size. When standard CEUS and 3D-CEUS were compared with the MDT decision, the sensitivity, specificity, positive predictive value, and negative predictive value were 96%, 100%, 100%, and 96%. A k statistic of 0.89 demonstrated consistency in detecting endoleaks and classifying type.
There were seven endoleaks for which the diagnosis was unclear on CTA. In six of these, CTA failed to differentiate between a type II and a type III endoleak. In the remaining case, CTA could not distinguish between a type I or type II endoleak. One type III endoleak on CTA was reclassified as a type II by CEUS, 3D-CEUS, and the MDT. Overall, seven patients underwent catheter angiography for diagnostic or treatment reasons, but this could have been avoided in three patients if the 3D-CEUS diagnosis was accepted as sac size was stable, but computed tomography could not rule out a type III endoleak in two cases and a type I endoleak in another. Examples of two cases for which CTA and CEUS failed to differentiate between type II and type III endoleaks that could be imaged on 3D-CEUS with the diagnosis confirmed by catheter angiography are illustrated in Figs 2 and 3 .
DISCUSSION
This study shows that 3D-CEUS is more sensitive than CTA to endoleak and more accurate at defining the source and type of endoleak. CTA failed to distinguish between type II and type III endoleak in six cases and between type I and type II in one other patient. These findings are important as type I and type III endoleaks are considered to be "high-pressure" leaks that may lead to aneurysm rupture and need urgent repair. Previously, invasive catheter angiography was indicated whenever the endoleak could not be accurately classified by CTA. This carried a risk of complications and was expensive. In this study, 3D-CEUS classified all indeterminate endoleaks on CTA and achieved almost complete agreement with the final decision made by the vascular MDT. Therefore, catheter angiography should be used only when treatment is required.
The sensitivity and specificity of ultrasound and CEUS have always been compared previously with CTA. 10, [13] [14] [15] 19 Our pilot study showed this to be unsafe as CTA may fail to detect endoleak and frequently fails to classify endoleaks accurately. 17 There is no precedent for using the MDT decision as the gold standard, but this was thought to be appropriate for this study as no single imaging modality, including catheter angiography, is 100% sensitive and specific. Obviously, it would not have been ethical to undertake catheter angiography in patients for whom there was not thought to be a need for treatment. The MDT decision was based on all available imaging including CTA, 3D-CEUS, and catheter angiography when this was needed. The MDT consisted of vascular surgeons, vascular radiologists, and vascular technologists not involved in the study to reduce bias as much as possible. CEUS is well documented to be more sensitive than CTA to low-flow endoleaks, which may still relate to sac growth. 13, 19 In this study, CEUS and 3D-CEUS failed to detect only one type I endoleak and one type II endoleak, achieving a sensitivity of 96% compared with both CTA and the MDT decision. The missed type I endoleak was small and in the very proximal neckdan area often difficult to image on ultrasound. The missed type II endoleak was also small and found in a patient for whom the interval between CTA and 3D-CEUS was 14 days; it is possible that this endoleak was intermittent or thrombosed in the intervening period. In this case, the AAA size was stable and no treatment was needed. The agreement between operators for both the detection and classification of endoleaks using 3D-CEUS was encouraging (k ¼ 0.89). This included the identification of the source vessel for every endoleak; the ability to accurately delineate inflow and outflow vessels is important in the planning of interventions. 13 Currently, many vascular surgeons and endovascular therapists are more familiar with CTA as they are able to manipulate the images in three planes, to perform reconstructions, and to take advantage of various visualization tools. As 3D-CEUS achieves multiplanar reconstructions from a single sweep of the transducer, the clinician can view and scroll through the 3D reconstruction slice by slice, akin to CTA images. The images can be interpreted in axial, coronal, and transverse planes, ensuring that adjacent vessels are not mistaken for endoleaks. An additional benefit of imaging in three planes simultaneously is that the operator does not miss areas of interest during manual rotation of the transducer; this allows confident identification and classification of even small leaks. Finally, the facility to segment the 3D-CEUS retains the advantages of dynamic imaging with duplex ultrasound. Flow velocities through the stent graft can be used to measure severity of stenosis or limb kinking. Plain radiographs are still needed to detect stent fracture or migration, but these are usually treated conservatively unless a complication ensues. 1 
Fig 3.
One year after endovascular aneurysm repair (EVAR), computed tomography angiography (CTA) detected an endoleak close to the left limb of the graft (arrow) (a). A type III endoleak could not be excluded on CTA or contrast-enhanced ultrasound (CEUS). Both operators diagnosed a type II endoleak originating from the inferior mesenteric artery on three-dimensional (3D)-CEUS. As the aneurysm was increasing in size, catheter angiography was undertaken, confirming a type IIa endoleak (arrow), which was embolized successfully (b). There has been no further abdominal aortic aneurysm (AAA) growth on subsequent surveillance.
Fig 2.
One year after endovascular aneurysm repair (EVAR), computed tomography angiography (CTA) detected an endoleak closely related to the flow divider of the stent graft (arrow) (a). Neither CTA nor standard contrast-enhanced ultrasound (CEUS) could differentiate between a type II and a type III endoleak. Both three-dimensional (3D)-CEUS operators diagnosed a type II endoleak, and this was confirmed on catheter angiography (arrow) (b). As the aneurysm size was stable, duplex ultrasound surveillance was continued. This is the first adequate study on 3D-CEUS for surveillance after EVAR. Gargiulo and colleagues 20 recently reported on "four-dimensional" CEUS using a matrix transducer (Â6-1; Philips Medical Systems) to investigate endoleak in 22 patients after EVAR. Although four-dimensional CEUS was equivalent to CTA for endoleak detection, there were only three endoleaks, and the authors failed to explain how their images were acquired. Matrix ultrasound transducers have a limited field of view, and we are not told whether single or multiple acquisitions were performed for each patient. As it is essential to image the entire stent graft before endoleak can be confidently excluded, a tracked freehand system has the advantage that it allows imaging of the entire infrarenal aorta with one sweep of the probe. Although recruitment was consecutive and nonselective, 57 patients undergoing CTA preferred not to take part or could not be scheduled for CTA and CEUS studies within a month. Additional patients were lost because of instrument failure (failure of tracking sensors) and SonoVue supply problems. The frequency of endoleaks at 51% was higher than expected in a typical surveillance cohort. As our surveillance program is ultrasound based, patients undergoing CTA are more likely to have an endoleak as CTA is usually reserved for treatment planning or confirmation of diagnosis made on duplex ultrasound examination. A further limitation of this study was that many CTA and 3D-CEUS studies could not be performed on the same day, usually for logistical reasons. It is unlikely that an interval of <4 weeks had an important effect on our results, particularly as most patients had paired studies on the same day. We attempted to eliminate bias of the MDT members to an imaging modality by having multiple radiologists, surgeons, and vascular scientists within the team but who were not involved in the study. This study was performed using a prototype system that did not reach the commercial market. However, a CE-marked system (Piur tUS; www. piurimaging.com) is now available and works on similar principles. Finally, the clinical applicability of this study may be limited as the use of standard CEUS is not yet global.
3D-CEUS acquisition and display is not "real time"; this is equally true for CTA. As 3D-CEUS images can be interpreted in the light of the real-time 2D images acquired at the same time, this is not a significant shortcoming. 3D-CEUS is also subject to the same limitations as all ultrasound modalities are; bowel gas and obesity can make imaging difficult. An experienced operator can often disperse bowel gas or the scan can be repeated at another time. Only two CEUS and 3D-CEUS images were unsuitable for analysis in our study.
Our practice is now to arrange standard duplex ultrasound before discharge after EVAR with all patients undergoing CTA at 3 months. In the absence of type I or type III endoleak, subsequent surveillance is by standard duplex ultrasound and abdominal radiography. In the event of aneurysm growth >4 mm on standard duplex ultrasound, 3D-CEUS is performed to define any endoleak, although our vascular surgeons still prefer to book CTA before planning treatment. Any new endoleak seen on duplex ultrasound, even with a stable AAA diameter, is investigated by 3D-CEUS to classify the endoleak as we do not think that standard duplex ultrasound is satisfactory to accurately classify endoleaks. Proven type II endoleaks are then followed up using standard duplex ultrasound surveillance. If a type I or type III leak is diagnosed, CTA is undertaken to plan treatment. We also use 3D-CEUS selectively after the first follow-up CTA if there is any diagnostic uncertainty. Multimodality imaging is helpful to the MDT in challenging cases.
CONCLUSIONS
3D-CEUS was more sensitive than CTA for endoleak detection after EVAR and more accurate in its classification. The interoperator reliability for reporting both the detection and type of endoleak was excellent. 3D-CEUS is inexpensive, is relatively quick to perform, and has little or no known risks to the patient. 3D-CEUS is now our initial investigation of choice in cases of aneurysm sac expansion or diagnostic uncertainty after EVAR. 
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